LegalJul 8, 2026, 08:06 AM
Prime Medicine Wins Arbitration Against Beam Therapeutics
AI Summary
Prime Medicine, Inc. announced it received a final arbitration award on July 6, 2026, in its dispute with Beam Therapeutics, Inc. The Tribunal declared that Prime Medicine's development candidate, PM647 for Alpha-1 Antitrypsin Deficiency, falls within its defined "Field" under their 2019 Collaboration and License Agreement, confirming no breach by Prime Medicine. Consequently, Beam's requests for damages and injunctive relief were denied, and all other claims from both parties were also denied.
Key Highlights
- Prime Medicine received a final arbitration award on July 6, 2026.
- The Tribunal ruled that PM647 is within Prime Medicine's 'Field' under the 2019 Collaboration and License Agreement.
- The ruling confirmed Prime Medicine did not breach the Agreement with Beam Therapeutics.
- Beam Therapeutics' requests for damages and injunctive relief were denied.
- All remaining claims brought by both Beam and Prime Medicine were denied by the Tribunal.
Price Impact
More from PRME